Document is current
Any future updates will be listed below
-
Authors
Mills, Matthew N.
Naz, Afrin
Thawani, Chetna
Walker, Chelsea
Figura, Nicholas B.
Kushchayev, Sergiy
Oliver, Daniel E.
Etame, Arnold B.
Yu, Hsiang-Hsuan Michael
Robinson, Timothy J.
Liu, James K. C.
Vogelbaum, Michael A.
Forsyth, Peter A.
Czerniecki, Brian J.
Soliman, Hatem H.
Han, Hyo S.
Ahmed, Kamran A.
- License Information
-
More Information
Article History
Received: 8 March 2021
Accepted: 28 April 2021
First Online: 15 May 2021
Declarations
:
: The University of South Florida Institutional Review Board (ID Pro00023399) approved the present study. The need for consent to participate was waived by the University of South Florida Institutional Review Board, as the present study was a retrospective protocol that utilized anonymized data. Permission to access the data was approved by the University of South Florida Institutional Review Board.
: Not applicable.
: Hyo S. Han declares that she has received a speaker’s honorarium from Lilly Pharmaceuticals, research funding from Abbvie, Tesaro, TapImmune, Novartis, Bristol-Myers Squibb, Pfizer, SeattleGenetics, Prescient, Horizon, and Karyopharm. Peter A. Forsyth has received research funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb and Genentech. Michael A. Vogelbaum has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai. Brian J Czerniecki has intellectual property on a HER2 dendritic cell vaccine. Hsiang-Hsuan Michael Yu has received spearker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie.
